EMA Withdrawn: Avaglim (rosiglitazone;glimepiride) — SmithKline Beecham Ltd

View source ↗

Summary

Avaglim (rosiglitazone; glimepiride) has been withdrawn from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Avaglim (rosiglitazone)

Snippet

Status: Withdrawn. Therapeutic area: Diabetes Mellitus, Type 2. MAH: SmithKline Beecham Ltd. Decision date: 26/07/2011